Physician Views: Will Gilead's Biktarvy hit the ground running?

As expected, the FDA has approved Biktarvy, Gilead Sciences' once-daily single-tablet regimen for the treatment of HIV; it is forecast to be a multi-billion dollar franchise for the company. Adoption of Biktarvy could have significant commercial implications for GlaxoSmithKline and utilisation of its Tivicay-based regimens.

How motivated will patients and prescribers be to switch from their current regimen and how quickly will adoption of Biktarvy occur?

We are snap-polling HIV specialists in the US and EU5 markets to get a better understanding…

The FDA approved Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single-tablet regimen (STR) for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA <50 c/mL). No dosage adjustment of Biktarvy is required in patients with estimated creatinine clearance greater than or equal to 30 mL per minute. Biktarvy does not require testing for HLA-B*5701, has no food intake requirements, and has no baseline viral load or CD4 count restrictions. Approval is pending in the EU.

Do you think there will be significant motivation from patients and/or physicians to switch from dolutegravir-containing regimens to bictegravir-containing regimens?

Yes

No

Those patients who are motivated to switch from dolutegravir-containing regimens to bictegravir-containing regimens; do you think a significant proportion of them will look to do so proactively before their next scheduled physician visit?

Yes

No

At what speed do you think Biktarvy will be adopted among switching patients during its first 12 months on the market?

Very slowly

Slowly

Moderately

Quickly

Very quickly

At what speed do you think Biktarvy will be adopted among treatment-naïve patients during its first 12 months on the market?

Very slowly

Slowly

Moderately

Quickly

Very quickly

What additional impact would rapid inclusion of Biktarvy into treatment guidelines have on early rates of adoption?

No impact

Marginal impact

Moderate impact

Significant impact

Very significant

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions. Note: FirstWord Polls are powered by Medefield MedePolls, a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties and over 100 markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

To read more Physician Views articles, click here.

Reference Articles